Qiagen Past Earnings Performance
Past criteria checks 1/6
Qiagen has been growing earnings at an average annual rate of 13.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 4.1% per year. Qiagen's return on equity is 2.6%, and it has net margins of 4.7%.
Key information
13.9%
Earnings growth rate
13.9%
EPS growth rate
| Life Sciences Industry Growth | 20.2% |
| Revenue growth rate | 4.1% |
| Return on equity | 2.6% |
| Net Margin | 4.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Qiagen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,966 | 93 | 569 | 191 |
| 30 Jun 24 | 1,940 | 73 | 568 | 194 |
| 31 Mar 24 | 1,939 | 337 | 570 | 195 |
| 31 Dec 23 | 1,965 | 341 | 579 | 199 |
| 30 Sep 23 | 1,954 | 332 | 587 | 197 |
| 30 Jun 23 | 1,978 | 337 | 593 | 198 |
| 31 Mar 23 | 1,999 | 353 | 599 | 198 |
| 31 Dec 22 | 2,142 | 423 | 604 | 190 |
| 30 Sep 22 | 2,226 | 488 | 618 | 178 |
| 30 Jun 22 | 2,261 | 539 | 616 | 177 |
| 31 Mar 22 | 2,313 | 563 | 606 | 180 |
| 31 Dec 21 | 2,252 | 513 | 584 | 190 |
| 30 Sep 21 | 2,240 | 311 | 604 | 184 |
| 30 Jun 21 | 2,190 | 480 | 572 | 182 |
| 31 Mar 21 | 2,065 | 449 | 549 | 162 |
| 31 Dec 20 | 1,870 | 359 | 525 | 149 |
| 30 Sep 20 | 1,713 | 191 | 522 | 137 |
| 30 Jun 20 | 1,612 | 14 | 517 | 142 |
| 31 Mar 20 | 1,550 | -31 | 530 | 151 |
| 31 Dec 19 | 1,526 | -41 | 530 | 157 |
| 30 Sep 19 | 1,516 | -25 | 502 | 164 |
| 30 Jun 19 | 1,511 | 196 | 492 | 164 |
| 31 Mar 19 | 1,507 | 188 | 508 | 163 |
| 31 Dec 18 | 1,502 | 190 | 497 | 162 |
| 30 Sep 18 | 1,496 | 90 | 476 | 162 |
| 30 Jun 18 | 1,482 | 78 | 474 | 158 |
| 31 Mar 18 | 1,453 | 55 | 466 | 157 |
| 31 Dec 17 | 1,418 | 40 | 478 | 154 |
| 30 Sep 17 | 1,387 | 89 | 467 | 145 |
| 30 Jun 17 | 1,362 | 75 | 480 | 143 |
| 31 Mar 17 | 1,347 | 82 | 480 | 147 |
| 31 Dec 16 | 1,338 | 80 | 470 | 150 |
| 30 Sep 16 | 1,320 | 123 | 485 | 157 |
| 30 Jun 16 | 1,296 | 123 | 471 | 157 |
| 31 Mar 16 | 1,281 | 126 | 450 | 148 |
| 31 Dec 15 | 1,281 | 130 | 445 | 147 |
| 30 Sep 15 | 1,293 | 104 | 475 | 151 |
| 30 Jun 15 | 1,315 | 105 | 484 | 157 |
| 31 Mar 15 | 1,326 | 113 | 487 | 162 |
| 31 Dec 14 | 1,345 | 116 | 490 | 164 |
| 30 Sep 14 | 1,345 | 151 | 487 | 163 |
| 30 Jun 14 | 1,331 | 157 | 487 | 156 |
| 31 Mar 14 | 1,315 | 72 | 487 | 152 |
| 31 Dec 13 | 1,302 | 69 | 486 | 146 |
Quality Earnings: QGE2 has a large one-off loss of $387.2M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: QGE2's current net profit margins (4.7%) are lower than last year (17%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QGE2 has become profitable over the past 5 years, growing earnings by 13.9% per year.
Accelerating Growth: QGE2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: QGE2 had negative earnings growth (-72%) over the past year, making it difficult to compare to the Life Sciences industry average (5.4%).
Return on Equity
High ROE: QGE2's Return on Equity (2.6%) is considered low.